Anixa Biosciences Inc (ANIX)
3.57
+0.10
(+2.88%)
USD |
NASDAQ |
Nov 05, 16:00
3.57
0.00 (0.00%)
After-Hours: 20:00
Anixa Biosciences Net Income (Quarterly): -3.277M for July 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| July 31, 2024 | -3.277M |
| April 30, 2024 | -3.139M |
| January 31, 2024 | -3.255M |
| October 31, 2023 | -2.69M |
| July 31, 2023 | -2.511M |
| April 30, 2023 | -2.288M |
| January 31, 2023 | -2.322M |
| October 31, 2022 | -3.476M |
| July 31, 2022 | -2.746M |
| April 30, 2022 | -3.544M |
| January 31, 2022 | -3.829M |
| October 31, 2021 | -4.013M |
| July 31, 2021 | -4.334M |
| April 30, 2021 | -2.399M |
| January 31, 2021 | -2.208M |
| October 31, 2020 | -2.224M |
| July 31, 2020 | -2.562M |
| April 30, 2020 | -2.640M |
| January 31, 2020 | -2.592M |
| October 31, 2019 | -2.088M |
| July 31, 2019 | -2.14M |
| April 30, 2019 | -2.538M |
| January 31, 2019 | -4.882M |
| October 31, 2018 | -5.302M |
| July 31, 2018 | -5.477M |
| Date | Value |
|---|---|
| April 30, 2018 | -1.378M |
| January 31, 2018 | -1.838M |
| October 31, 2017 | -1.786M |
| July 31, 2017 | -1.794M |
| April 30, 2017 | 0.1605M |
| January 31, 2017 | -1.589M |
| October 31, 2016 | -1.048M |
| July 31, 2016 | -1.104M |
| April 30, 2016 | -1.272M |
| January 31, 2016 | -1.593M |
| October 31, 2015 | -1.292M |
| July 31, 2015 | -1.602M |
| April 30, 2015 | -2.237M |
| January 31, 2015 | 3.752M |
| October 31, 2014 | -3.153M |
| July 31, 2014 | 0.411M |
| April 30, 2014 | -3.249M |
| January 31, 2014 | -3.614M |
| October 31, 2013 | -2.927M |
| July 31, 2013 | -2.582M |
| April 30, 2013 | -2.476M |
| January 31, 2013 | -2.095M |
| October 31, 2012 | -1.860M |
| July 31, 2012 | -0.6291M |
| April 30, 2012 | -0.8771M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-4.334M
Minimum
Jul 2021
-2.208M
Maximum
Jan 2021
-2.95M
Average
-2.69M
Median
Oct 2023
Net Income (Quarterly) Benchmarks
| Annovis Bio Inc | -5.020M |
| Akero Therapeutics Inc | -55.99M |
| ACADIA Pharmaceuticals Inc | 33.39M |
| Amicus Therapeutics Inc | -15.70M |
| Intra-Cellular Therapies Inc | -26.32M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 3.592M |
| EPS Diluted (Quarterly) | -0.10 |
| Enterprise Value | 89.84M |
| Earnings Yield | -10.92% |
| Normalized Earnings Yield | -10.08 |